Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19
Jurjan Aman, Erik Duijvelaar, Liza Botros, Azar Kianzad, Job Schippers, Patrick Smeele, Sara Azhang, Imke Bartelink, Pierre Bet, Wim Boersma, Karin Boomars, Peter Bonta, Lieuwe Bos, Job Van Bragt, Gert-Jan Braunstahl, Lucas Celant, Katrien Eger, Miranda Geelhoed, Yurika Van Glabbeek, Hans Grotjohan, Laura Hagens, Chris Happe, Leo Heunks, Michel Van Den Heuvel, Wouter Hoefsloot, Rianne Hoek, Romke Hoekstra, Herman Hofstee, Arthur Vanhove, Nicole Juffermans, Marije Lammers, Renate Kos, Marleen Kemper, Peter Kunst, Ivo Van Der Lee, Laurien Van Der Lee, Pearl Mau-Asam, Anke-Hilse Maitland-Van Der Zee, Adinda Mieras, Esther Nossent, Marieke Overbeek, Laurien Oswald, Nienke Paternotte, Carol Pamplona, Niels Pronk, Michiel De Raaf, Elise Slob, Ary Serpa Neto, Marcus Schultz, Marry Smit, Frank Smeenk, Josien Smits, Janneke Stalenhoef, Pieter Roel Tuinman, Jeroen Wessels, Jessy Van Wezenbeek, Anton Vonk Noordegraaf, Frances Handoko-De Man, Harm Jan Bogaard
European Respiratory Journal Sep 2021, 58 (suppl 65) OA4119; DOI: 10.1183/13993003.congress-2021.OA4119
